Literature DB >> 31833149

Alterations in genetic pathways following radiotherapy for head and neck cancer.

Arash O Naghavi1, Youngchul Kim2, George Q Yang1, Kamran A Ahmed1, Jimmy J Caudell1.   

Abstract

BACKGROUND: Radiotherapy (RT) is an integral component in the treatment of head and neck cancer (HNC).We hypothesized there would be alterations in gene-expression and pathway activity in HNC samples obtained in recurrent HNC that were previously treated with RT, when compared to RT-naïve disease.
METHODS: Patient data was abstracted from a prospectively maintained database. Linear-microarray analysis and supervised gene-set enrichment-analysis were employed to compare RT-naive and recurrent disease after prior-RT.
RESULTS: A total of 157 patients were analyzed, 96 (61%) were RT-naive and 61 (39%) had RT.After radiation, there was upregulation of genes associated with angiogenesis, protein-translation-machinery, cell-cycle regulation, and growth factors, and downregulation associated with Myc activity, and hypoxic response (all P < .001).Previously irradiated HNC was associated with downregulation in 19/42 genes in the Wnt/B-catenin-pathway (P = .045)and 119/199 genes involved in the MYC target pathway (P = .024).
CONCLUSION: Patients with recurrences salvaged surgically post-RT had significant alterations in gene-expression and in Wnt/B-catenin and MYC-target pathways. These pathways may represent potential targets to prevent development of resistance to RT.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  genetic pathways; head and neck cancer; radioresistance; radiotherapy

Mesh:

Year:  2019        PMID: 31833149      PMCID: PMC7771332          DOI: 10.1002/hed.26004

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  38 in total

Review 1.  Wnt/beta-catenin signaling in development and disease.

Authors:  Hans Clevers
Journal:  Cell       Date:  2006-11-03       Impact factor: 41.582

Review 2.  Dysregulated molecular networks in head and neck carcinogenesis.

Authors:  Alfredo A Molinolo; Panomwat Amornphimoltham; Cristiane H Squarize; Rogerio M Castilho; Vyomesh Patel; J Silvio Gutkind
Journal:  Oral Oncol       Date:  2008-09-19       Impact factor: 5.337

3.  Final results of local-regional control and late toxicity of RTOG 9003: a randomized trial of altered fractionation radiation for locally advanced head and neck cancer.

Authors:  Jonathan J Beitler; Qiang Zhang; Karen K Fu; Andy Trotti; Sharon A Spencer; Christopher U Jones; Adam S Garden; George Shenouda; Jonathan Harris; Kian K Ang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-03-07       Impact factor: 7.038

Review 4.  Targeting tumor hypoxia in nasopharyngeal carcinoma.

Authors:  Bo Hong; Vivian Wai Yan Lui; Masumi Hashiguchi; Edwin Pun Hui; Anthony Tak-Cheung Chan
Journal:  Head Neck       Date:  2011-11-22       Impact factor: 3.147

Review 5.  Implementing personalized medicine in a cancer center.

Authors:  David A Fenstermacher; Robert M Wenham; Dana E Rollison; William S Dalton
Journal:  Cancer J       Date:  2011 Nov-Dec       Impact factor: 3.360

Review 6.  Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis.

Authors:  Jean Bourhis; Jens Overgaard; Hélène Audry; Kian K Ang; Michele Saunders; Jacques Bernier; Jean-Claude Horiot; Aurélie Le Maître; Thomas F Pajak; Michael G Poulsen; Brian O'Sullivan; Werner Dobrowsky; Andrzej Hliniak; Krzysztof Skladowski; John H Hay; Luiz H J Pinto; Carlo Fallai; Karen K Fu; Richard Sylvester; Jean-Pierre Pignon
Journal:  Lancet       Date:  2006-09-02       Impact factor: 79.321

7.  Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial.

Authors:  Jens Overgaard; Hanne Sand Hansen; Lena Specht; Marie Overgaard; Cai Grau; Elo Andersen; Jens Bentzen; Lars Bastholt; Olfred Hansen; Jørgen Johansen; Lisbeth Andersen; Jan F Evensen
Journal:  Lancet       Date:  2003-09-20       Impact factor: 79.321

8.  FLT1 kinase is a mediator of radioresistance and survival in head and neck squamous cell carcinoma.

Authors:  Evert Jan Van Limbergen; Piotr Zabrocki; Michaël Porcu; Esther Hauben; Jan Cools; Sandra Nuyts
Journal:  Acta Oncol       Date:  2013-09-16       Impact factor: 4.089

9.  CMTM4 is frequently downregulated and functions as a tumour suppressor in clear cell renal cell carcinoma.

Authors:  Ting Li; Yingying Cheng; Pingzhang Wang; Wenyan Wang; Fengzhan Hu; Xiaoning Mo; Hongxia Lv; Tao Xu; Wenling Han
Journal:  J Exp Clin Cancer Res       Date:  2015-10-16

Review 10.  Glioblastoma Stem Cells Microenvironment: The Paracrine Roles of the Niche in Drug and Radioresistance.

Authors:  Alessia Fidoamore; Loredana Cristiano; Andrea Antonosante; Michele d'Angelo; Erica Di Giacomo; Carlo Astarita; Antonio Giordano; Rodolfo Ippoliti; Elisabetta Benedetti; Annamaria Cimini
Journal:  Stem Cells Int       Date:  2016-01-06       Impact factor: 5.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.